Receptor discordance in metastatic breast cancer lesions associated with poorer overall survival in a retrospective cohort study
When breast cancer changes its targets, does the current treatment still work?
This single-center retrospective cohort study analyzed 436 paired lesion samples from patients with primary and metastatic breast cancer. Re…
Breast cancer often changes its targets, and when tumors lose the proteins doctors rely on, survival drops from 95 to 70 months depending on…
Case report describes embolization and endocrine therapy for post-biopsy hematoma in prostate cancer patient
A Rare Bruise After Prostate Biopsy — What Every Man Should Know
A case report and literature review describes a prostate cancer patient who developed extensive subcutaneous hematoma after transperineal pr…
Large bruising after prostate biopsy is uncommon, but knowing how it looks can get treatment started quickly.
Sequential paclitaxel-palbociclib showed no difference in ORR versus reverse sequence in ER+/HER2- breast cancer.
New Test Predicts Who Needs Chemo in Breast Cancer
This randomized phase II trial evaluated sequential administration of paclitaxel and palbociclib with endocrine therapy in patients with ER+…
Doctors now have a way to spot patients who can skip chemo and go straight to safer hormone treatment.